

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/763,807	
				Filing Date		January 22, 2004	
				First Named Inventor		Shanler	
				Group Art Unit		1617	
Examiner Name		Kendra D. Carter					
Sheet	1	of	2	Attorney Docket No.		136519.00101	
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Figures Appear	
		Number Kind Code (if known)					
	A1	2007/0225217	A1	Chappell et al.	09-27-2007		
	A2	2005/0281772	A1	Bromley et al.	12-22-2005		
	A3	2007/0225631	A1	Bowlin et al.	09-27-2007		
	A4	2005/0020600	A1	Scherer	01-27-2005		
	A5	2009/0130027	A1	Shanler et al.	05-21-2009		
	A6	6,335,023	B1	Yu et al.	01-01-2002		
	A7	6,824,786	B2	Yu et al.	11-30-2004		
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Figures Appear	T
		Office Number Kind Code (if known)					
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
	C1	Bamford et al. "Rosacea: Current Thoughts on Origin" 2001, Seminars in Cutaneous Medicine and Surgery, 20(3):199-206					
	C2	Crawford et al. "Rosacea: I. Etiology, Pathogenesis, and Subtype Classification" 2004, J. Am. Acad. Dermatol., 51(3):324-41					
	C3	Cunliffe et al. "Clonidine and Facial Flushing in Rosacea" 1977, British Med. J., 105					
	C4	Sams "Untoward Response with Topical Fluoruracil" 1968, Arch. Dermatol. 97(1): 14-22					
Examiner Signature				Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,807
				Filing Date	January 22, 2004
				First Named Inventor	Shanler
				Group Art Unit	1617
				Examiner Name	Kendra D. Carter
Sheet	2	of	2	Attorney Docket No.	136519.00101
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.			
	C5	Collagenex Corporation/IMS Demand Study as presented at The Fourth Annual Healthcare Conference, November 27-28, 2007, New York, NY			
	C6	van Zuuren et al. "Systematic Review of Rosacea Treatments" 2007, J. Am. Acad. Dermatol. 56:107-115			
	C7	Powell "Clinical Practice: Rosacea" 2005, N. Engl. J. Med. 352(8):793-803			
Examiner Signature				Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.